Vilon vs Cardiogen: which Khavinson peptide actually has evidence behind it

A reader in one of the peptide forums I follow asked me last week whether Cardiogen was worth adding alongside Vilon for a cardiovascular-longevity stack. Short answer: run Vilon if the Khavinson-school approach interests you at all, and skip Cardiogen, because the "evidence" attached to Cardiogen in most peptide directories is not actually about the Cardiogen peptide.

Both compounds come out of the same Russian research tradition, the Khavinson bioregulator peptides, short sequences that are claimed to cross into the nucleus and switch gene expression on and off in a tissue-specific way. Vilon targets the thymus and immune system. Cardiogen targets cardiomyocytes, the heart muscle cells. On paper they sound like a matched pair for two different organ systems. In practice, the evidence quality between them is nowhere close.

The evidence gap is the whole story here

I try to stay evidence-based with peptides, and this is one of the clearer cases I've run into where two compounds from the same family land in completely different places. Vilon has a real, if dated, human trial record. Researchers found improved coagulation and immune markers along with reduced insulin requirements in elderly diabetics, and a separate study found reduced disseminated intravascular coagulation complications in type-1 diabetes patients. There's also a case series showing improved survival and fewer complications in elderly stage-III colorectal cancer patients given Vilon alongside standard treatment. That's three separate human cohorts, published in Russian gerontology and medical journals, all pointing the same direction on immune function and metabolic markers in older adults.

Cardiogen has none of that. Zero human trials, zero animal studies, nothing peptide-specific at all. What some directories list as "9 human studies" for Cardiogen turns out to be a name collision. That figure actually traces back to CardioGen-82, a completely unrelated rubidium-82 PET imaging generator used in cardiac diagnostic scans, plus a Hungarian cardiomyopathy patient registry that happens to share part of the name. Someone built an automated citation matcher years ago, it grabbed the wrong papers, and that error has been propagating through peptide directories ever since. I flag this because I see it repeated as fact in enough places that people are making decisions based on evidence that doesn't exist.

What the mechanism claims actually rest on

Both peptides share the same underlying theoretical mechanism: they're proposed to bind DNA promoter regions and reactivate gene expression that has gone quiet with age, in a tissue-specific way. The in-vitro chromatin work backing that general mechanism, selective heterochromatin decondensation in aging cells, was done on the family broadly, not on Cardiogen specifically. Vilon at least has its own dedicated epigenetic work on top of that shared foundation, showing it increased SIRT1 and decreased PARP1/PARP2 expression in aging human mesenchymal stem cells. Cardiogen has nothing of its own layered on top. It's riding entirely on the family's general theoretical framework with no compound-specific confirmation that it does what it's claimed to do in cardiac tissue.

I've been through enough of these directory entries at this point to know the pattern: when a compound has thin evidence, the marketing copy tends to lean harder on the mechanism story to compensate. That's exactly what's happening with Cardiogen.

Cost and side-effect load don't tell you much either

Here's where it gets less useful as a deciding factor. Both peptides are priced similarly as small synthetic dipeptides or short-chain sequences from the same manufacturers, and the reported side-effect profile across the whole Khavinson family is mild in the literature that exists: occasional injection-site irritation, an early transient headache in some users. Neither compound distinguishes itself on cost or tolerability, so this comparison lives or dies on the evidence, not the practical logistics.

The real practical risk with either one is supply chain, not the molecule itself. Khavinson-family peptides are among the most counterfeited compounds in the research-peptide space, largely because buyers are sourcing from forum links with no reliable way to check identity or purity. That risk is worse for Cardiogen precisely because there's so little independent literature to check a vendor's claims against. If a seller tells you their Cardiogen tested at 98% purity, you have almost nothing published to sanity-check that claim against. With Vilon at least there's a real research trail giving you something to compare against.

Who actually fits each one

Vilon makes sense for someone specifically drawn to the Khavinson-school approach to immune support and longevity, who goes in understanding this is Russian-cohort data and in-vitro cell work, not large Western randomized trials. If your priority is a well-evidenced thymic immune peptide with a stronger Western data trail, thymosin alpha-1 covers similar ground with better documentation, and it's worth reading up on before you commit to the Khavinson family specifically. For a broader look at how peptide research quality gets misrepresented in directories and marketing, our piece on whether peptides are dangerous covers the same due-diligence habits that apply here.

Cardiogen is a harder recommendation. I wouldn't build a protocol around a compound with zero peptide-specific data, human or animal, especially when the number that's supposed to justify it turns out to belong to an unrelated PET imaging product. If cardiovascular support is the actual goal, that goal is better served elsewhere until real Cardiogen-specific research shows up. This verdict is specific to this one compound's current evidence base, not a judgment on the broader Khavinson family.

If you do decide to run Vilon, the Russian-school protocol is a short course, typically 10 to 20 consecutive days, repeated two to three times per year, with community subcutaneous dosing converging around 100 to 200 mcg per day during the cycle. That's the real-world number people are actually using, not a Western-validated dose, since none exists for this peptide family.

Now the part my lawyer makes me say, and he's right: the doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.

If you're weighing a broader stack rather than just these two, our guide to building a fat-loss peptide stack walks through the mechanism-layering approach I use when deciding what actually earns a spot in a protocol versus what's there on reputation alone. Vilon earns its spot on the evidence. Cardiogen, as it stands today, does not.